Landmark Hospitals Compassionate Use Study for Critical COVID-19 Patients Evidences Potential for Allogenic Biologic Product

Landmark Hospitals Compassionate Use Study for Critical COVID-19 Patients Evidences Potential for Allogenic Biologic Product

Landmark Hospital manages six long-term acute care hospitals across the Southeast United States and recently announced its decision to offer an investigational allogenic biologic product derived from amniotic fluid to patients with advanced COVID-19 conditions under...
HHMI-backed Johns Hopkins Hosted Team Investigates Use of Alpha Blockers (Prazosin) to Combat a Deadly COVID-19 Condition: Cytokine Storm

HHMI-backed Johns Hopkins Hosted Team Investigates Use of Alpha Blockers (Prazosin) to Combat a Deadly COVID-19 Condition: Cytokine Storm

Although considered eccentric toward the end, Howard Hughes was incredibly rich and put that capital to work in many interesting and important ways, including what has become one of the largest private funding organizations for biological medical research in the...
UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

University of California Irvine, (UCI) recently announced their participation in a COVID-19-focused clinical trial investigating a drug called Aviptadil in at risk patients. Dr. Richard Lee, Interim chief of UCK Health Division of Pulmonary Diseases and Critical Care...

Pin It on Pinterest